These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3825604)

  • 1. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis].
    de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH
    Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of the plasma aluminum concentration of hemodialysis patients].
    Kuleva V; Petrov I; Antonov S; Kiriakov Z
    Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 7. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial evaluation of aluminum concentrations in patients with nephropathy and undergoing hemodialysis at the Miguel Pérez Carreño Hospital and the University Hospital of Caracas (Venezuela)].
    Parra OE; Navarro JA; de Ardila M; Weissinger J; Domínguez J; Gutiérrez LE; Carlini R; Mendoza JA; Salgado OJ; Romero RA
    Invest Clin; 1989; 30(4):193-203. PubMed ID: 2488708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of aluminum in hemodialysis patients.
    Sandhu G; Djebali D; Bansal A; Chan G; Smith SD
    Am J Kidney Dis; 2011 Mar; 57(3):523-5. PubMed ID: 21257246
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum kinetics in patients treated with hemodialysis or hemofiltration with sorbent recycling of ultrafiltrate.
    Shapiro WB; Schilb TP; Porush JG
    Trans Am Soc Artif Intern Organs; 1984; 30():342-6. PubMed ID: 6533906
    [No Abstract]   [Full Text] [Related]  

  • 12. [Causes of hyperaluminemia in patients maintained on hemodialysis].
    Balezina OA; Ermolenko VM; Bel'skii NK; Nebol'sina LA; Segel'man VS
    Ter Arkh; 1982; 54(7):85-6. PubMed ID: 7135231
    [No Abstract]   [Full Text] [Related]  

  • 13. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 14. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of elevated serum aluminum levels in adult dialysis patients.
    Jaffe JA; Liftman C; Glickman JD
    Am J Kidney Dis; 2005 Aug; 46(2):316-9. PubMed ID: 16112051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aluminum-related bone disease in chronic hemodialysis patients].
    Jara A; Rosenberg H; Bruhn C; Vaccarezza A; Vial S; Jalil R; Cisternas H
    Rev Med Chil; 1993 Jul; 121(7):769-76. PubMed ID: 8296081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of toxic metals in blood and urine samples of chronic renal failure patients, before and after dialysis.
    Kazi TG; Jalbani N; Kazi N; Jamali MK; Arain MB; Afridi HI; Kandhro A; Pirzado Z
    Ren Fail; 2008; 30(7):737-45. PubMed ID: 18704823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the value of plasma/serum aluminum in patients with chronic renal failure?
    Winney RJ; Cowie JF; Robson JS
    Clin Nephrol; 1985; 24 Suppl 1():S2-8. PubMed ID: 3842104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypercalcemia and hyperaluminemia in children with chronic renal insufficiency].
    Hinojosa-Lezama M; Gordillo-Paniagua G; Muñoz-Arizpe R; Mercado-Polo L
    Bol Med Hosp Infant Mex; 1987 Sep; 44(9):535-9. PubMed ID: 3663320
    [No Abstract]   [Full Text] [Related]  

  • 20. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.